Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07117474
PHASE1
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension: a Randomized, Double-blind, Placebo-controlled Phase I Study.
Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
View on ClinicalTrials.gov
Summary
To evaluate the safety and tolerability of a single subcutaneous injection of HRS-9563 in hypertensive subjects
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2024-12-24
Completion Date
2025-12
Last Updated
2025-08-12
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
HRS-9563, placebo
A single subcutaneous injection of HRS-9563 injection or placebo was administered
Locations (1)
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China